Embolization Particle Market (2026 - 2033)

Embolization Particle Market Summary

The global embolization particle market size was valued at USD 368.9 million in 2025 and is projected to grow from USD 394.6 million in 2026 to USD 661.8 million by 2033, growing at a CAGR of 7.7% from 2026 to 2033. North America dominated the market with the largest revenue share of 36.2% in 2025. The market encompasses minimally invasive embolic technologies used to selectively occlude blood vessels and control, reduce, or redirect blood flow during image-guided procedures.

These technologies are utilized across interventional radiology, oncology, gynecology, and vascular care, particularly for the management of hypervascular tumors, uterine fibroids, arteriovenous malformations, and selected cases of hemorrhage and peripheral vascular conditions. Market development is supported by the growing adoption of image-guided interventions as alternatives or adjuncts to open surgery, the expansion of interventional radiology services, the increasing availability of advanced catheter-based procedures, and a greater emphasis on targeted treatment with reduced procedural morbidity.

The rising prevalence of cancers requiring tumor embolization procedures is driving market demand by expanding the number of patients undergoing vascular-based tumor interventions. Cancers such as hepatocellular carcinoma and metastatic liver tumors can require embolization to restrict the blood supply supporting tumor growth. As the number of patients requiring these interventions increases, the volume of tumor embolization procedures also expands, creating greater demand for embolization particles used to occlude tumor-feeding vessels. The growing clinical use of embolization as part of locoregional cancer management further supports particle utilization, particularly among patients with tumors that are unsuitable for surgical resection or require targeted vascular treatment. Increasing use of repeat and sequential embolization procedures for selected tumors can also contribute to recurring demand for embolization particles.

Liver tumors, particularly hepatocellular carcinoma and certain metastatic liver tumors, may require embolization to restrict the blood supply to the tumor and achieve localized treatment effects. As more patients require locoregional management, the number of embolization procedures increases, creating greater demand for embolization particles used to occlude tumor-feeding blood vessels. The use of embolization in patients who are not suitable candidates for surgical resection further expands the potential treatment population. In addition, repeated or sequential embolization procedures for selected patients can lead to repeated use of embolization particles. According to the data published by the WHO in 2026, the following graph shows that scientists at the International Agency for Research on Cancer (IARC) estimated that a substantial number of people worldwide were diagnosed with liver cancer and died from the disease in 2024.

The increasing incidence and clinical burden of uterine fibroids are driving market demand by expanding the number of patients requiring effective, uterus-preserving, and minimally invasive treatment options. Symptomatic uterine fibroids can cause heavy menstrual bleeding, pelvic pain and pressure, anemia, and fertility-related complications, often requiring active intervention. As patients and healthcare providers prefer alternatives to major surgical procedures such as hysterectomy, Uterine Artery Embolization (UAE) has gained importance as a minimally invasive treatment approach. During UAE, embolization particles are delivered through a catheter into the uterine arteries to reduce blood flow to the fibroids, resulting in ischemia and gradual shrinkage of the lesions. The minimally invasive nature of the procedure, reduced surgical burden, shorter recovery time, and uterus-preserving characteristics make it an attractive option for appropriately selected patients.

For instance, data published by FIGO in 2025, uterine fibroids affect up to 70% of women by menopause, with the burden reported to be particularly high among African women, where incidence has been estimated at around 80%. Although generally benign, fibroids can cause heavy menstrual bleeding, chronic anemia, infertility, miscarriage, early labor, postpartum hemorrhage, and disruptions to bladder, bowel, and sexual function.

The increasing demand for minimally invasive vascular interventions is driving market growth, as healthcare providers favor catheter-based procedures over open surgery for managing vascular conditions. Advances in interventional radiology, imaging guidance, catheter technology, and selective vascular access have expanded the use of endovascular procedures across conditions such as peripheral vascular hemorrhage, arteriovenous malformations, aneurysms, pseudoaneurysms, hypervascular tumors, and other abnormal vascular conditions. Embolization enables targeted occlusion of specific blood vessels via a catheter, reducing the need for large surgical incisions and potentially shortening recovery and hospital stays. The increasing adoption of outpatient and day-case vascular interventions is further supporting this shift toward less invasive treatment approaches.

The growing availability of interventional radiology consultants and the expansion of dedicated IR centers are driving market growth by increasing capacity for image-guided vascular procedures. A larger and more specialized IR workforce enables hospitals to diagnose and treat a broader range of conditions requiring embolization, including peripheral hemorrhage, hypervascular tumors, vascular malformations, aneurysms, pseudoaneurysms, and other peripheral vascular disorders. The establishment of dedicated IR suites also improves access to minimally invasive procedures and strengthens referral pathways from oncology, vascular surgery, gastroenterology, urology, and emergency care departments. As more healthcare facilities develop specialized IR capabilities, procedures that previously required surgical intervention can be managed through catheter-based approaches. For instance, data published by The Royal College of Radiologists in 2025 UK on IR consultants by city is shown in the graph.

Market Dynamics

The embolization particle industry is being shaped by increasing demand for minimally invasive, image-guided interventions across a broad range of vascular and nonvascular conditions. The expanding use of embolization in the management of uterine fibroids, hypervascular tumors, peripheral vascular hemorrhage, arteriovenous malformations, aneurysms, pseudoaneurysms, and other vascular abnormalities is increasing the clinical need for particulate embolic agents. Embolization allows physicians to selectively reduce or block blood flow to targeted vessels through catheter-based procedures, providing an alternative to more invasive surgical approaches. In addition, the growing adoption of interventional radiology, improvements in imaging and catheterization technologies, increasing preference for uterus-preserving and outpatient procedures, and greater awareness of minimally invasive treatment options are supporting procedure volumes.

Market Characteristics

The embolization particle industry is characterized by a competitive landscape shaped by established medical device manufacturers and specialized regional companies with differentiated embolization technologies. Market participants compete through product consistency, particle-size precision, material properties, delivery convenience, clinical performance, regulatory approvals, and expansion across a broader range of embolization procedures. Established products benefit from accumulated clinical evidence, physician familiarity, hospital relationships, and established distribution networks, while smaller and specialized companies focus on technological innovation and targeted clinical applications. Regulatory requirements, clinical validation, manufacturing standards, and the need for reliable particle characteristics create barriers to entry for new participants.

The embolization particle industry is experiencing continuous technological development across particle composition, size calibration, morphology, delivery systems, and therapeutic functionality. Manufacturers are improving particle uniformity and size precision to enable more controlled vascular occlusion and enhance procedural predictability. Innovation is also focused on drug-eluting particles that combine embolization with localized drug delivery, while hydrogel-based and advanced synthetic polymer materials are being developed to improve biocompatibility, swelling behavior, durability, and handling characteristics. Prefilled syringes and ready-to-use delivery formats support simpler procedural preparation and improved workflow efficiency. In addition, application-specific development is expanding the use of embolization particles across uterine fibroid embolization, prostate artery embolization, tumor embolization, hemorrhage control, aneurysm treatment, and peripheral vascular interventions, creating opportunities for differentiated particle designs and improved treatment outcomes.

In July 2025, Sirtex Medical announced that its SIR-Spheres Y-90 Resin Microspheres received U.S. FDA approval for the treatment of unresectable hepatocellular carcinoma. The expanded indication extended the use of the microsphere-based radioembolization therapy to another major liver cancer application, complementing its existing indication for metastatic colorectal cancer. SIR-Spheres uses personalized dosimetry to deliver radiation directly to tumors through the hepatic arteries, supporting patient-specific treatment planning.

Merger and acquisition activity in the embolization particle industry is supporting portfolio expansion, technology diversification, and broader capabilities across interventional and vascular therapies. Companies are pursuing acquisitions to obtain complementary technologies, strengthen manufacturing and distribution networks, expand relationships with hospitals and physicians, and enter adjacent therapeutic areas. These transactions can also provide access to established regulatory approvals, clinical expertise, and specialized product portfolios, reducing the time required to develop capabilities internally. Increasing consolidation across the interventional medical device sector is encouraging companies to combine complementary technologies and expand their presence across embolization, oncology, vascular intervention, and hemostasis procedures.

Regulatory requirements significantly impact the embolization particle industry, as these products must undergo rigorous evaluation of safety, performance, biocompatibility, manufacturing consistency, and clinical effectiveness before commercialization. Regulatory authorities require manufacturers to demonstrate that particle characteristics such as size distribution, material composition, sterility, delivery performance, and vascular occlusion behavior meet applicable standards. Changes in intended use or expansion into new clinical applications can require additional clinical evidence and regulatory submissions, influencing product development timelines and commercialization strategies. Differences in regulatory pathways across major markets can also increase compliance requirements for companies seeking international market access.

The end user concentration in the embolization particle industry reflects the specialized infrastructure, trained interventional specialists, and imaging capabilities required to perform embolization procedures. Hospitals account for a substantial share of end-user demand because they generally provide comprehensive interventional radiology facilities, multidisciplinary clinical teams, advanced imaging systems, and emergency care capabilities required for complex embolization procedures. Ambulatory surgical centers are gaining relevance as selected embolization procedures shift toward shorter-stay, outpatient settings, while specialty clinics and vascular centers are expanding their roles in elective and application-specific interventions.

Structure Insights

The calibrated spherical microspheres segment led the market, accounting for 65.7% of revenue in 2025. Their uniform shape and controlled size distribution provide predictable embolization and consistent vascular occlusion. The availability of calibrated particle sizes allows interventional radiologists to select particles based on vessel diameter, lesion characteristics, and the desired embolization depth. Their spherical geometry also supports smoother catheter delivery and more controlled distribution within the target vasculature. These characteristics are particularly important in tumor embolization, vascular malformations, hemorrhage control, aneurysm-related procedures, and other peripheral interventions.

Non-spherical/irregular particles are expected to exhibit significant growth, as they remain clinically useful in applications where predictable particle geometry is less critical. Their irregular surfaces can promote particle interactions, aggregation, and mechanical occlusion of vessels, thereby enabling effective embolization in several peripheral vascular procedures. These particles also benefit from established clinical experience and comparatively straightforward manufacturing, which can support cost-sensitive adoption, particularly in developing healthcare markets.

Function Insights

The plain/non-drug-eluting embolics segment led the market with the largest revenue share of 73.1% in 2025. They have broad applicability across peripheral embolization procedures where the primary objective is mechanical vessel occlusion rather than localized drug delivery. These embolics are used for indications such as hemorrhage control, vascular malformations, aneurysms, pseudoaneurysms, hypervascular tumors, and other peripheral vascular conditions. Their established clinical use, wide range of particle sizes and materials, straightforward deployment, and familiarity among interventional radiologists support continued utilization across hospitals and IR centers. Unlike drug-eluting embolics, they do not require drug loading or integration with a chemotherapy regimen, making their use operationally simpler across a wider range of procedures.

Drug-eluting embolics are expected to be the fastest-growing segment within the function category, supported by the increasing use of embolization as a platform for both vascular occlusion and localized drug delivery. These embolics combine the mechanical effect of vessel blockage with controlled delivery of therapeutic agents, particularly in transarterial chemoembolization for hepatocellular carcinoma and other hypervascular tumors. Their ability to deliver higher drug concentrations directly to the target lesion while limiting systemic exposure provides a strong clinical rationale for adoption.

Material Insights

The PVA-based materials segment led the market, with a revenue share of 30.4% in 2025. PVA particles have been used in embolization for decades across applications such as hemorrhage control, vascular malformations, tumor embolization, and other peripheral vascular procedures. Their availability in different particle sizes allows physicians to select materials based on the target vessel anatomy and desired embolization level. In addition, PVA-based microspheres have evolved to provide more uniform particle dimensions and improved delivery characteristics, helping address some limitations of conventional irregular PVA particles.

Hydrogel-based materials are expected to be the fastest-growing segment within the material category, driven by their favorable elasticity, compressibility, tunable properties, and potential for multifunctional embolization. Hydrogel microspheres can deform during catheter delivery and recover their shape after exiting the microcatheter, enabling deeper and more controlled penetration into smaller vessels. Their structure can also support drug loading, controlled release, imaging functionality, and other advanced therapeutic features, making them particularly attractive for interventional oncology and targeted embolization.

Particle Size Insights

The 100-300 µm segment led the market with the largest revenue share of 28.6% in 2025. This size range is widely available across major embolic platforms, including PVA-based particles, tris-acryl gelatin microspheres, and hydrogel microspheres, reflecting broad clinical acceptance. Its versatility makes it suitable for tumor embolization, vascular malformations, hemorrhage management, and other peripheral interventions where excessive distal penetration can increase the risk of non-target embolization. Clinical practice also frequently uses 100-300 µm particles in procedures such as prostate artery embolization. The combination of predictable deposition, established physician familiarity, and broad product availability supports its leading position.

The <100 µm particle-size range is expected to be the fastest-growing segment, driven primarily by increasing demand for deeper and more selective embolization. Smaller microspheres can penetrate more deeply into the distal vascular network, making them attractive for procedures in which occlusion of smaller feeding vessels is clinically desirable. The size range is incorporated into multiple embolic platforms, including tris-acryl gelatin, PVA-based hydrogel, and other microsphere technologies.

Delivery Format Insights

The vial segment led the market with the largest revenue share of 59.2% in 2025. Vial-based products allow clinicians to withdraw the required particle volume and mix it with saline, contrast media, or other preparation fluids as needed. This format is available across several established embolic particle platforms and supports a range of particle sizes and concentrations. Vials also provide convenient storage, established sterile packaging, and flexibility in adjusting the final embolic suspension, making them suitable for diverse embolization procedures.

Prefilled syringes are expected to be the fastest-growing delivery format because they simplify preparation and can reduce the number of handling steps before embolization. The embolic particles are supplied in a ready-to-use suspension, allowing clinicians to connect the syringe to the delivery system after appropriate preparation and contrast mixing. This can improve procedural workflow, reduce preparation time, and minimize handling-related variability. Prefilled formats are already available across established microsphere platforms and are increasingly attractive as IR centers focus on efficient procedure turnover and standardized workflows.

Application Insights

The tumor embolization segment led the market with the largest revenue share of 32.7% in 2025. Particularly established in liver-directed procedures, including transarterial embolization and chemoembolization, where particles can selectively occlude tumor-feeding arteries. The ability to achieve targeted vascular occlusion while preserving surrounding tissue makes particulate embolization relevant across several tumor types and treatment settings. The increasing use of minimally invasive cancer therapies, the expansion of interventional oncology services, and the greater availability of image-guided procedures continue to support the use of particles.

Prostate artery embolization is expected to be the fastest-growing application segment, supported by increasing clinical acceptance of PAE as a minimally invasive treatment option for lower urinary tract symptoms associated with benign prostatic hyperplasia. Recent clinical guidance recognizes PAE with particle embolics as an option for appropriately selected patients, strengthening its position within interventional urology. The procedure uses microspheres or PVA particles to selectively reduce blood flow to the prostate, offering an alternative to more invasive surgical approaches.

End Use Insights

The tumor embolization segment led the market with the largest revenue share of 80.2% in 2025. They provide comprehensive infrastructure, multidisciplinary specialists, imaging systems, and emergency care capabilities required for a wide range of embolization procedures. Hospitals are equipped to manage complex cases involving severe hemorrhage, hypervascular tumors, vascular malformations, aneurysms, and other peripheral vascular conditions. They also maintain established interventional radiology departments and catheterization or angiography suites, enabling continuous access to image-guided embolization.

Ambulatory Surgical Centers (ASCs) are expected to be the fastest-growing end-use segment as an increasing proportion of selected embolization procedures can be performed in outpatient or short-stay settings. Procedures such as prostate artery embolization and selected uterine fibroid and peripheral vascular embolization interventions can be performed with minimally invasive techniques and limited post-procedure observation, making them suitable for appropriately selected patients.

Regional Insights

North America dominated the embolization particle market with the largest revenue share of 36.2% in 2025, due to its established interventional radiology infrastructure, increasing adoption of minimally invasive vascular procedures, and availability of advanced image-guided treatment facilities. The region benefits from a large network of hospitals and specialized centers equipped to perform embolization procedures across oncology, hemorrhage control, vascular malformations, aneurysms, uterine fibroids, and other vascular conditions. In the U.S., the presence of experienced interventional radiologists, advanced imaging capabilities, established reimbursement pathways, and increasing clinical adoption of particle-based embolization supports procedural demand. Canada is also expanding the use of interventional radiology services, particularly through specialized hospitals and tertiary care centers.

U.S. Embolization Particle Market Trends

The embolization particle market in the U.S. is supported by the continued use of embolization in the management of cerebral Arteriovenous Malformations (AVMs). Cerebral AVMs involve abnormal connections between arteries and veins that can increase the risk of intracranial bleeding and other neurological complications. Endovascular embolization can reduce blood flow through these abnormal vessels and may be performed as a standalone intervention or as part of a broader treatment strategy. The availability of specialized neurovascular centers, advanced imaging technologies, and experienced interventional specialists supports the utilization of embolization procedures for cerebral AVMs. For instance, data published by the American Heart Association in 2024 indicate that brain arteriovenous malformations are rare vascular lesions characterized by abnormal connections between dysplastic cerebral arteries and veins. The estimated prevalence of bAVMs is 1.3 per 100,000 person-years, and the detection rate for symptomatic bAVMs is 0.94 per 100,000 person-years. The rarity of the condition and the presence of asymptomatic patients make the actual disease burden difficult to determine.

The market is also supported by the liver cancer burden in the U.S., particularly hepatocellular carcinoma, which represents the major form of primary liver cancer. Patients with liver tumors who are unsuitable for surgical resection or require locoregional management may undergo transarterial embolization-based procedures to restrict blood flow to the tumor. The continued need for tumor-directed interventions, combined with established interventional oncology capabilities and specialized treatment centers, drives increased utilization of embolization particles and supports market growth.

Estimated Number of Liver Cancer Deaths by State, U.S., 2026

Source: American Cancer Society 2026

Europe Embolization Particle Market Trends

The embolization particle market in Europe is growing significantly due to the increasing adoption of minimally invasive embolization procedures across oncology, vascular, and benign disease applications. The region has a well-established interventional radiology infrastructure supporting embolization for hepatocellular carcinoma, metastatic liver tumors, arteriovenous malformations, renal tumors, and uterine fibroids. The expanding use of transarterial procedures for liver tumors is particularly supporting demand, as embolization provides a locoregional treatment option for patients who may not be suitable for surgical intervention. In addition, the availability of specialized interventional radiology centers, trained specialists, advanced imaging technologies, and multidisciplinary cancer care is facilitating wider use of embolization procedures.

The UK embolization particle market is supported by the increasing burden of kidney and renal tumors, which is expanding the patient population requiring interventional treatment. The growing incidence of kidney cancer is creating greater demand for treatment approaches that can manage tumors in patients who are unsuitable for surgery, require preoperative intervention, or need control of tumor-related bleeding. Renal artery embolization can reduce blood flow to kidney tumors by selectively occluding tumor-feeding vessels, helping control vascularity and associated symptoms. As the number of patients diagnosed with renal tumors increases, the potential pool of patients requiring embolization-based interventions also expands, supporting greater utilization of embolization particles. The established interventional radiology infrastructure in the UK, combined with increasing physician expertise in image-guided procedures, facilitates the adoption of minimally invasive approaches for selected renal tumors.

For instance, data published by Cancer Research UK, kidney cancer incidence in the UK is projected to increase by 14% between 2024-2026 and 2038-2040, with approximately 21,900 new kidney cancer cases expected annually by 2038-2040. This projected increase in kidney cancer cases is expected to expand the patient pool requiring renal tumor management, including selected embolization procedures, thereby supporting demand for embolization particles in the UK.

The embolization particle market in Germany is growing due to the increasing use of embolization for uterine fibroids, liver tumors, and vascular malformations, supported by the country’s well-developed hospital and interventional radiology network. A key contributor is the growing preference for minimally invasive alternatives to open surgery, particularly for patients who require targeted treatment but may not be suitable candidates for conventional surgical procedures. The increasing availability of specialized interventional radiology units and advanced angiographic imaging is enabling physicians to perform more selective embolization procedures with greater precision. In addition, Germany’s aging population and associated rise in cancer and vascular disorders are expanding the number of patients who may require embolization-based interventions.

Asia Pacific Embolization Particle Market Trends

The embolization particle market in the Asia Pacific is growing due to the expanding adoption of interventional radiology, increasing cancer treatment volumes, and improving access to image-guided minimally invasive procedures across China, Japan, India, South Korea, and Australia. The high burden of hepatocellular carcinoma and other hypervascular tumors supports the use of embolization in interventional oncology, particularly through transarterial procedures. In parallel, the increasing availability of specialized interventional radiology departments and improved imaging infrastructure is allowing hospitals to perform more targeted embolization procedures.

Japan embolization particle market is growing due to the established use of interventional radiology in cancer and vascular disease management, supported by a well-developed healthcare infrastructure and increasing preference for minimally invasive procedures. The high clinical burden of hepatocellular carcinoma continues to drive demand for transarterial embolization and transarterial chemoembolization, in which embolization particles are used to achieve targeted vascular occlusion. In addition, the use of embolization techniques in procedures such as portal vein embolization, splenic artery embolization, and treatment of selected vascular abnormalities contributes to broader clinical utilization. Japan’s aging population also increases the need for minimally invasive management of cancer and vascular conditions. The availability of specialized hospitals and experienced interventional radiologists facilitates the adoption of advanced embolization techniques.

• According to the World Economic Forum, Japan's Ministry of Internal Affairs and Communications reported that, as of 2024, the country had a record 36.25 million people aged 65 and over, accounting for 29.3% of the total population. This share is projected to rise to 34.8% in 2040 and 36.3% in 2045. Japan's proportion of elderly residents is already far higher than second-ranked Martinique (25.3%), making it the world's most aged society.

The embolization particle market in India is growing as the expansion of interventional oncology is increasing the number of procedures requiring targeted vascular occlusion. Liver cancer management is an important contributor, with transarterial chemoembolization incorporated into treatment pathways for patients who are not suitable for surgery or local ablation. The availability of drug-eluting beads and other embolic materials is also broadening procedural options for interventional radiologists. Beyond liver tumors, embolization is being utilized for gastrointestinal bleeding, pseudoaneurysms, vascular malformations, preoperative tumor devascularization, and portal vein interventions, widening the addressable clinical base.

Latin America Embolization Particle Market Trends

The embolization particle market in Latin America is growing as interventional oncology gradually expands beyond a limited number of high-volume referral centers, creating opportunities for wider adoption of particle-based embolization. Transarterial chemoembolization remains an established locoregional approach for intermediate-stage liver cancer, generating recurring demand for embolic materials, while transarterial embolization is also being used for selected vascular and bleeding-related conditions. The market is supported by the development of specialized angiography facilities, greater availability of image-guided procedures, and increasing clinical experience with minimally invasive treatment.

Middle East and Africa Embolization Particle Market Trends

The embolization particle market in MEA is growing as healthcare infrastructure is upgraded and interventional radiology capabilities expand across major tertiary-care and cancer centers. Investment in new hospitals, angiography suites, advanced imaging systems, and specialized oncology facilities is improving the capacity to perform image-guided embolization procedures. The rising cancer burden is another important demand driver, particularly as the number of cancer cases in the Eastern Mediterranean region is projected to increase substantially over the coming decades, increasing the need for locoregional and minimally invasive treatment options.

Key Embolization Particle Company Insights

Key market players are shaping the industry through continuous innovation in embolic material technology and image-guided delivery systems. Innovations such as improved particle-size uniformity, enhanced vascular penetration, controlled embolization, greater radiopacity, and improved catheter compatibility are enabling more precise and predictable vessel occlusion during interventional procedures. Manufacturers are also focusing on developing particles with improved handling characteristics and controlled distribution within target vessels, particularly for tumor embolization and other vascular applications. Advances in drug-eluting and imaging-visible embolic technologies are further enabling more targeted treatment while improving procedural visualization.

Key Embolization Particle Companies

The following key companies have been profiled for this study on the embolization particle market:

• Merit Medical Systems

• Boston Scientific Corporation

• Siemens Healthineers

• Terumo Corporation

• Sirtex Medical

• Instylla, Inc.

• IMBiotechnologies Ltd.

• NEXTBIOMEDICAL CO., LTD. 

• Suzhou Hengrui Medical Equipment Co., Ltd.

• Magle PharmaCept GmbH.

• Pfizer Inc.

• Crannmed

Competitive Benchmarking

Recent Developments

• In January 2026, NEXTBIOMEDICAL announced that Nexsphere-F, a fast-resorbable embolization microsphere, received approval from Health Canada for musculoskeletal pain embolization. The microsphere is designed to temporarily occlude abnormal blood vessels associated with osteoarthritis-related pain and subsequently dissolve after the procedure, distinguishing it from permanent embolization particles.

• In November 2025, Canyon Medical announced that its SureSphere and BlocSphere PVA Embolization Microspheres received both U.S. FDA 510(k) clearance and approval from the National Medical Products Administration (NMPA). The products are available in six calibrated particle sizes ranging from 75 to 1,200 μm, enabling more controlled and targeted embolization across different vessel sizes. The microspheres are designed to be highly compressible and resilient, supporting delivery through catheters while maintaining stable embolization after deployment.

• In September 2025, Merit Medical announced that its Embosphere Microspheres received CE Marking in the European Union for genicular artery embolization to treat knee osteoarthritis. The expanded indication extends the established use of embolization microspheres into musculoskeletal embolization, where selective reduction of blood flow to inflamed synovial tissue is intended to reduce pain and improve joint function.

Embolization Particle Market Report Scope

Global Embolization Particle Market Report Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends across each sub-segment from 2021 to 2033. For this study, Grand View Research has segmented the global embolization particle market report based on structure, function, material, particle size, delivery format, application, end use, and region:

• Structure Outlook (Revenue, USD Million, 2021 - 2033)

  • Calibrated Spherical Microspheres

  • Non-Spherical/Irregular Particles

  • Sponge/Foam Embolic Particles

• Function Outlook (Revenue, USD Million, 2021 - 2033)

  • Plain/Non-Drug-Eluting Embolics

  • Drug-Eluting Embolics

• Material Outlook (Revenue, USD Million, 2021 - 2033)

  • PVA-Based Materials

  • Acrylic/Other Synthetic Polymer-Based Materials

  • Hydrogel-Based Materials

  • Gelatin-Based Materials

• Particle Size Outlook (Revenue, USD Million, 2021 - 2033)

  • <100 µm

  • 100-300 µm

  • 300-500 µm

  • 500-700 µm

  • 700-900 µm

  • ≥900 µm

• Delivery Format Outlook (Revenue, USD Million, 2021 - 2033)

  • Prefilled Syringe

  • Vial

  • Other Delivery Formats

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Hemorrhage Control

    • Gastrointestinal Bleeding

    • Traumatic Hemorrhage

    • Postoperative/Iatrogenic Hemorrhage

    • Other Hemorrhage

  • Tumor Embolization

    • Hepatic Tumors

    • Renal Tumors

    • Other Hypervascular Tumors

  • Vascular Malformation Embolization

    • Peripheral AVMs

    • Cerebral AVMs

    • Other Vascular Malformations

  • Aneurysm/Pseudoaneurysm Embolization

    • Peripheral Aneurysms/Pseudoaneurysms

    • Visceral Aneurysms/Pseudoaneurysms

    • Other Aneurysms/Pseudoaneurysms

  • Uterine Fibroid Embolization

  • Prostate Artery Embolization

  • Portal Vein Embolization

  • Other Particle-Based Embolization

    • Other Peripheral Embolization

    • Other Organ Embolization

    • Other Particle-Based Applications

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals

  • Ambulatory Surgical Centers

  • Specialty Clinics

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Norway

    • Denmark

    • Sweden

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • MEA

    • Saudi Arabia

    • South Africa

    • UAE

    • Kuwait